drugset / Trial / NCT02843061
Combination of Rituximab and NK Immunotherapy for B Lymphoma
Phase 1/2
Completed
30 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
Timeline
- Start
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK immunotherapy | Cell therapy | 1e+10 cells | Intravenous |
| Subject | Rituximab | Monoclonal antibody | — | — |